期刊
PHARMACOGENOMICS
卷 20, 期 17, 页码 1235-1245出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2019-0121
关键词
gene polymorphism; methotrexate; pharmacogenetics; rheumatoid arthritis
资金
- Ministry of Education, Science and Technological Development of the Republic of Serbia [175091]
For many decades, methotrexate (MXT) has remained the drug of choice in the treatment of rheumatoid arthritis (RA). Unfortunately, a considerable number of patients do not achieve an appropriate therapeutic response. Pharmacogenetics studies do not give usable results regarding differences in MTX response among RA patients. The mechanism of MTX action in RA is not completely understood. We present and discuss data regarding the molecular basis of folate and adenosine pathways, the most obvious MTX targets, to explain possible causes of therapy failure. The molecular basis of the disease could also have an impact on therapy outcomes and in this review we explore this. Finally, we make a short review of available pharmacogenetics study results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据